Last updated: October 22, 2026
Editorial Scope and Principles
CefaHub publishes practical, independently framed information about U.S. cephalexin, the historical Keflex brand, generic products, dosage forms, infection-specific clinical questions and lawful access to prescriptions. Each page should answer its primary question, distinguish evidence from assumptions and avoid repeating another page merely to capture a related search phrase.
Medical education does not authorize self-diagnosis or switching an antibiotic. We do not produce invented prescribers, online pharmacy rankings, guaranteed inventory claims, fixed national prices or unsupported clinical superiority statements.
Evidence Standards Depend on the Claim
Product approval, marketing status, therapeutic equivalence and NDC listing are different regulatory concepts. We use the FDA Orange Book for approved drug-product evidence, FDA NDC guidance for labeler-submitted identifiers and the exact DailyMed cephalexin label for formulation-specific information. These records do not guarantee real-time availability.
Clinical recommendations are evaluated separately from a product label. For confirmed group A strep, CDC guidance lists penicillin or amoxicillin as preferred agents and limits cephalexin use in immediate-type penicillin hypersensitivity. For abscesses and cellulitis, IDSA skin infection guidance emphasizes distinctions such as drainage, nonpurulent infection and resistance. Those examples demonstrate why an FDA indication is not automatically a current first-line recommendation.
| Claim type | Preferred evidence | Important limit |
|---|---|---|
| FDA product approval / equivalence | Drugs@FDA and Orange Book | Not proof of live inventory |
| Cephalexin strength and formulation | Exact current product labeling / DailyMed | May not describe other manufacturer products |
| Drug side effects, renal dosing, pregnancy | Label plus high-quality clinical evidence | Not individual medical advice |
| GAS pharyngitis recommendations | CDC condition-specific guidance | Clinical diagnosis and allergies still matter |
| SSTI / MRSA questions | IDSA and up-to-date clinical evidence | Abscess management may require drainage |
| Pharmacy licensing | FDA BeSafeRx and state pharmacy boards | Advertising is not licensing |
| Cost, coverage and shipping | Actual pharmacy or plan terms | Static price cannot predict checkout |
Product and Dosage-Form Precision
Cephalexin capsules, tablet records and reconstituted oral suspension cannot be described as one generic package. Liquid 125 mg/5 mL and 250 mg/5 mL have different concentrations; dosing instructions are patient-specific. Some current capsule labels document 333 mg and 750 mg strengths in addition to 250 mg and 500 mg. A label record, however, is not evidence that a particular store stocks that presentation.
Keflex brand records must be described as historical where appropriate. We differentiate brand discontinuation from withdrawal for safety or effectiveness, the presence of approved generic products and the ability to fill a particular prescription. Manufacturer, applicant, labeler, distributor and packager should not be treated as synonyms.
Safety and Clinical Comparisons
Comparison content identifies the actual medicines, organisms, approved uses, clinical context and material risks. Cephalexin versus amoxicillin is different from cephalexin versus doxycycline or topical mupirocin: common illness keywords do not establish therapeutic equivalence. We avoid converting guideline examples into general instructions to start or switch treatment.
We prioritize correction of statements affecting allergies, kidney-function assessment, use during pregnancy or breastfeeding, serious adverse effects, MRSA assumptions and selection of antibiotics for upper urinary versus bladder infections. When evidence does not support a definitive claim, the limitation should be explicit.
Affiliates, Commercial Referrals and Price Information
Some pages may contain sponsored or affiliate links to independent businesses. Any compensation relationship should be disclosed and does not certify pharmacy legitimacy, availability, safety or appropriate treatment. We do not write clinical conclusions to favor referral partners.
Cost content is designed to remain useful without unverified dollar quotes: readers should compare the same authorized form, strength, quantity, network and payment terms, and ask for the actual final quote. Pharmacy or telehealth listings cannot promise prescription approval or same-day supply.
Review Attribution, Dates and Corrections
Editorial fact checking, link validation and style editing are not a medical review. Only an actual, documented assessment by a qualified and consenting professional can be represented as completed clinical review. Our Medical Review Process and Reviewer Standards explain the distinction.
A reader may report an error by using Contact CefaHub with the exact URL and evidence. Corrections should consider the source’s date, the affected claim and whether nearby pages need consistent changes. We may update or withdraw unsupported statements; a report does not guarantee a requested outcome or personal reply.